Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey.
暂无分享,去创建一个
[1] Erwin G. Van Meir,et al. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.
[2] L. Aguilar,et al. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. , 2005, Arthritis and rheumatism.
[3] D. Edwards,et al. Metalloproteinases and their inhibitors in tumor angiogenesis , 2005, International journal of cancer.
[4] G. Pilkington,et al. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. , 1996, Cancer letters.
[5] Marco Presta,et al. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. , 2003, Blood.
[6] David A. Cheresh,et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.
[7] Gunilla Westergren-Thorsson,et al. Tumour necrosis factor‐α interacts with biglycan and decorin , 2002 .
[8] J. Bonner,et al. Inhibition of Platelet-derived Growth Factor-BB-induced Fibroblast Proliferation by Plasmin-activated -Macroglobulin Is Mediated via an -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein-dependent Mechanism (*) , 1995, The Journal of Biological Chemistry.
[9] Luigi Buonaguro,et al. HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.
[10] C. Kumar. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. , 2003, Current drug targets.
[11] Byungkyu Brian Park,et al. Visualization and analysis of protein interactions , 2003, Bioinform..
[12] M. Shibuya,et al. Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.
[13] A. Joseph,et al. Scatter factor binds to thrombospondin and other extracellular matrix components. , 1996, The American journal of pathology.
[14] S. Schultz-Cherry,et al. Transforming growth factor-beta complexes with thrombospondin. , 1992, Molecular biology of the cell.
[15] M. Stevens,et al. INVOLVEMENT OF α-2-MACROGLOBULIN RECEPTOR IN CLEARANCE OF INTERLEUKIN 8–α-2-MACROGLOBULIN COMPLEXES BY HUMAN ALVEOLAR MACROPHAGES , 2000 .
[16] R. Kalluri,et al. Endogenous inhibitors of angiogenesis. , 2005, Cancer research.
[17] Marco Presta,et al. Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight–Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[18] M. Simons,et al. Syndecan-4-mediated signalling. , 2001, Cellular signalling.
[19] F. Soncin. Angiogenin supports endothelial and fibroblast cell adhesion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Giacca,et al. Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides* , 1999, The Journal of Biological Chemistry.
[21] G. Neufeld,et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. , 2002, Trends in cardiovascular medicine.
[22] S. Kitano,et al. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor , 2002, Cancer Gene Therapy.
[23] J. Waltenberger,et al. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. , 1998, Experimental cell research.
[24] N. Ortéga,et al. Extracellular matrix‐bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] Salman Rahman,et al. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. , 2005, BMC cell biology.
[26] M. Nugent,et al. Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling , 2003, Journal of cellular biochemistry.
[27] T. Arima,et al. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). , 1994, Journal of biochemistry.
[28] D. Sheppard,et al. The Lymphangiogenic Vascular Endothelial Growth Factors VEGF-C and -D Are Ligands for the Integrin α9β1* , 2005, Journal of Biological Chemistry.
[29] J. Tiesman,et al. Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma. , 1993, The Journal of biological chemistry.
[30] S. Soker,et al. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. , 1994, Biochemical and biophysical research communications.
[31] I. Zachary,et al. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. , 2001, Biochemical and biophysical research communications.
[32] M. Iruela-Arispe,et al. ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165* , 2003, Journal of Biological Chemistry.
[33] G. Neufeld,et al. Glypican-1 Is a VEGF165 Binding Proteoglycan That Acts as an Extracellular Chaperone for VEGF165 * , 1999, The Journal of Biological Chemistry.
[34] M. Hahne,et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation , 2005, Cell Death and Differentiation.
[35] T. Deuel,et al. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. , 1999, Current opinion in hematology.
[36] Marco Presta,et al. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV‐1 Tat protein antagonists , 2004, FEBS letters.
[37] D. Coppola,et al. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors , 2004, Oncogene.
[38] R. Yu,et al. Role of tumor-associated gangliosides in cancer progression. , 2003, Biochimie.
[39] C. Rüegg,et al. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis , 2003, Cellular and Molecular Life Sciences CMLS.
[40] P. Comoglio,et al. Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.
[41] Guoping Wu,et al. Platelet Factor 4 and Interleukin-8 CXC Chemokine Heterodimer Formation Modulates Function at the Quaternary Structural Level* , 2005, Journal of Biological Chemistry.
[42] D. Gouma,et al. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. , 1993, Journal of immunology.
[43] I. Asplin,et al. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. , 2001, Blood.
[44] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[45] L. Trusolino,et al. Interactions between growth factor receptors and adhesion molecules: breaking the rules. , 2003, Current opinion in cell biology.
[46] B. Eliceiri. This Review is part of a thematic series on Integrins, which includes the following articles: Integrins and the Myocardium Functional Consequences of Integrin Gene Mutations in Mice Integrins in Vascular Development Integrin and Growth Factor Receptor Crosstalk , 2001 .
[47] E. Sage,et al. SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[48] M. Rusnati,et al. Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin‐like bFGF receptors , 1993, Journal of cellular physiology.
[49] T. Handel,et al. Chemokines bind to sulfatides as revealed by surface plasmon resonance. , 2005, Biochimica et biophysica acta.
[50] J. Turnbull,et al. Heparan sulfate: decoding a dynamic multifunctional cell regulator. , 2001, Trends in cell biology.
[51] M. Redondo-Horcajo,et al. Solution Structure and Interaction with Basic and Acidic Fibroblast Growth Factor of a 3-kDa Human Platelet Factor-4 Fragment with Antiangiogenic Activity* 210 , 2001, The Journal of Biological Chemistry.
[52] G. Woude,et al. HGF/SF-Met signaling in tumor progression , 2005, Cell Research.
[53] B. Matthews,et al. Three-dimensional structure of human basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[54] M. Lyon,et al. Hepatocyte growth factor/scatter factor and its interaction with heparan sulphate and dermatan sulphate. , 2003, Biochemical Society transactions.
[55] F. Amalric,et al. Fibroblast Growth Factor-2 Binds to the Regulatory β Subunit of CK2 and Directly Stimulates CK2 Activity toward Nucleolin* , 1996, The Journal of Biological Chemistry.
[56] I. Asplin,et al. The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. , 2000, The Journal of biological chemistry.
[57] Marco Presta,et al. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. , 2005, Current pharmaceutical design.
[58] E. Di Cera,et al. Thrombin Functions through Its RGD Sequence in a Non-canonical Conformation* , 2005, Journal of Biological Chemistry.
[59] K. Kimata,et al. Hepatocyte growth factor immobilized onto culture substrates through heparin and matrigel enhances DNA synthesis in primary rat hepatocytes. , 1994, Experimental cell research.
[60] T. Muramatsu,et al. Human Ryudocan from Endothelium-like Cells Binds Basic Fibroblast Growth Factor, Midkine, and Tissue Factor Pathway Inhibitor (*) , 1996, The Journal of Biological Chemistry.
[61] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[62] L. Kemény,et al. Identification of a soluble interleukin-8 inhibitor in the supernatant of polymorphonuclear leukocytes. , 1998, Immunology letters.
[63] G. Neufeld,et al. The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. , 2002, Advances in experimental medicine and biology.
[64] R. Kendall,et al. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.
[65] M. Capogrossi,et al. Platelet-derived Growth Factor-BB and Basic Fibroblast Growth Factor Directly Interact in Vitro with High Affinity* , 2002, The Journal of Biological Chemistry.
[66] J. Heino,et al. Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. , 1992, The Journal of biological chemistry.
[67] Dan M. Bolser,et al. Comparative interactomics analysis of protein family interaction networks using PSIMAP (protein structural interactome map) , 2005, Bioinform..
[68] D. Spillmann,et al. More to "heparin" than anticoagulation. , 1994, Thrombosis research.
[69] M. Giacca,et al. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. , 2005, Blood.
[70] K. Norrby. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165‐mediated mammalian angiogenesis , 2000, International journal of experimental pathology.
[71] K. Kent,et al. Activation of integrin receptors is required for growth factor-induced smooth muscle cell dysfunction. , 2000, Journal of vascular surgery.
[72] D. Ribatti. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review , 2005, British journal of haematology.
[73] A. Sahni,et al. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3 , 2004 .
[74] J. Massagué,et al. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system , 1991, Cell.
[75] P. Monini,et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. , 1999, Journal of immunology.
[76] I. Bernard-Pierrot,et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004, Oncogene.
[77] Christopher J. Robinson,et al. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.
[78] U. Cavallaro,et al. Fibronectin modulates endothelial response to HIV type 1 Tat. , 1997, AIDS research and human retroviruses.
[79] T. Nakamura,et al. Hepatocyte Growth Factor/Scatter Factor Binds with High Affinity to Dermatan Sulfate* , 1998, The Journal of Biological Chemistry.
[80] G. Camenisch,et al. ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * , 2002, The Journal of Biological Chemistry.
[81] R. Gallo,et al. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[82] M. Lyon,et al. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. , 1994, The Journal of biological chemistry.
[83] K. Matsumoto,et al. Hepatocyte growth factor specifically binds to sulfoglycolipids. , 1994, The Journal of biological chemistry.
[84] A. Nel,et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. , 1999, Journal of immunology.
[85] Marco Presta,et al. αvβ3-integrin-dependent activation of focal adhesion kinase mediates NF-κB activation and motogenic activity by HIV-1 Tat in endothelial cells , 2005, Journal of Cell Science.
[86] S. Jimenez,et al. Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[87] M. Dewhirst,et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[88] R. Hebbel,et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.
[89] A. Östman. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma , 2004 .
[90] P. Wingfield,et al. Heparin Binding and Oligomerization of Hepatocyte Growth Factor/Scatter Factor Isoforms , 1997, The Journal of Biological Chemistry.
[91] Takashi Morita,et al. Identification of Vascular Endothelial Growth Factor Receptor-binding Protein in the Venom of Eastern Cottonmouth , 2005, Journal of Biological Chemistry.
[92] T. McCaffrey,et al. Protection of transforming growth factor β activity by heparin and fucoidan , 1994 .
[93] M. Nasu,et al. Bioactivity of the Vascular Endothelial Growth Factor Trapped in Fibrin Clots: Production of IL-6 and IL-8 in Monocytes by Fibrin Clots , 2001, Pathophysiology of Haemostasis and Thrombosis.
[94] T. Muramatsu,et al. Midkine binds specifically to sulfatide the role of sulfatide in cell attachment to midkine-coated surfaces. , 2000, European journal of biochemistry.
[95] D. Rifkin,et al. Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1 , 1998 .
[96] M. Plank,et al. The Role of the Angiopoietins in Tumour Angiogenesis , 2004, Growth factors.
[97] D. Sane,et al. Vascular Origin of a Soluble Truncated Form of the Hepatocyte Growth Factor Receptor (c-met) , 2002, Circulation research.
[98] Y. Gho,et al. Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.
[99] Raghu Kalluri,et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[100] Ron Shamir,et al. PIVOT: Protein Interacions VisualizatiOn Tool , 2004, Bioinform..
[101] R. Schwall,et al. Sulfated Oligosaccharides Promote Hepatocyte Growth Factor Association and Govern Its Mitogenic Activity (*) , 1995, The Journal of Biological Chemistry.
[102] K. Garcia,et al. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. , 2000, The Journal of biological chemistry.
[103] T. Sasaki,et al. Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. , 1998, European journal of biochemistry.
[104] A. Sahni,et al. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. , 2000, Blood.
[105] D. Ribatti,et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. , 2004, Journal of medicinal chemistry.
[106] L. Naldini,et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.
[107] I. Screpanti,et al. Human immunodeficiency virus type 1 tat protein modulates fibronectin expression in thymic epithelial cells and impairs in vitro thymocyte development. , 1996, Cellular immunology.
[108] X. Wu,et al. A Two-site Model for ApoB Degradation in HepG2 Cells* , 1997, The Journal of Biological Chemistry.
[109] K. Zou,et al. LDL receptor-related protein as a component of the midkine receptor. , 2000, Biochemical and biophysical research communications.
[110] A. Albini,et al. Thrombospondin‐1 inhibits Kaposi's sarcoma (KS) cell and HIV‐1 Tat‐induced angiogenesis and is poorly expressed in KS lesions , 1999, The Journal of pathology.
[111] J. Weatherbee,et al. Transforming growth factor‐β1 binds to immobilized fibronectin , 1989 .
[112] R. Tanzi,et al. Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands , 2000, Nature Medicine.
[113] Asif Ahmed,et al. Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids , 2000, Laboratory Investigation.
[114] S. Soker,et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[115] M. Nugent,et al. pH Regulates Vascular Endothelial Growth Factor Binding to Fibronectin , 2004, Journal of Biological Chemistry.
[116] E. Ruoslahti,et al. A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin , 1993, The Journal of cell biology.
[117] M. Giacca,et al. Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans* , 2001, The Journal of Biological Chemistry.
[118] Y. Gho,et al. Specific interaction of VEGF165 with β‐amyloid, and its protective effect on β‐amyloid‐induced neurotoxicity , 2005 .
[119] K. Hayashi,et al. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan , 1992, The Journal of cell biology.
[120] D. Rifkin,et al. Plasminogen activators and matrix metalloproteinases in angiogenesis. , 1996, Enzyme & protein.
[121] H Lortat-Jacob,et al. Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat* , 2001, The Journal of Biological Chemistry.
[122] F. Carraro,et al. Role of inflammatory mediators in angiogenesis. , 2005, Current drug targets. Inflammation and allergy.
[123] J. Riordan,et al. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[124] A. Pozzi,et al. Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. , 1992, EXS.
[125] Erkki Ruoslahti,et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.
[126] N. Kaminski,et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.
[127] S. Stringer,et al. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. , 2003, The international journal of biochemistry & cell biology.
[128] A. Baird,et al. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. , 1995, Investigative ophthalmology & visual science.
[129] S. Ladisch,et al. Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. , 2001, Biochemical and biophysical research communications.
[130] J. Park,et al. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.
[131] Marco Presta,et al. αvβ3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells , 1997 .
[132] G. Barillari,et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. , 1999, Blood.
[133] Z. Fuks,et al. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis , 1990, Cancer and Metastasis Reviews.
[134] D. Rifkin,et al. Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. , 1989, The Journal of biological chemistry.
[135] S. L. Gonias,et al. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[136] A. Sahni,et al. Fibrinogen binding potentiates FGF‐2 but not VEGF induced expression of u‐PA, u‐PAR, and PAI‐1 in endothelial cells , 2004, Journal of thrombosis and haemostasis : JTH.
[137] A. Prats,et al. Antiangiogenic Properties of Fibstatin, an Extracellular FGF-2–Binding Polypeptide , 2004, Cancer Research.
[138] A. Bikfalvi,et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. , 1999, Blood.
[139] Andreas Sommer,et al. Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): Identification of two Asp‐Gly‐Arg‐Containing domains involved in the mitogenic activity of bFGF in endothelial cells , 1991, Journal of cellular physiology.
[140] L. Pellegrini,et al. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. , 2001, Current opinion in structural biology.
[141] A. Bikfalvi. Platelet factor 4: an inhibitor of angiogenesis. , 2004, Seminars in thrombosis and hemostasis.
[142] L. Lowe-Krentz,et al. Heparin releasable and nonreleasable forms of heparan sulfate proteoglycan are found on the surfaces of cultured porcine aortic endothelial cells , 1992, Molecular and Cellular Biochemistry.
[143] Y. Takada,et al. Specific Interaction of Angiostatin with Integrin αvβ3 in Endothelial Cells* , 2001, The Journal of Biological Chemistry.
[144] Richard G. W. Anderson,et al. Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Controls Endocytosis and c-CBL-mediated Ubiquitination of the Platelet-derived Growth Factor Receptor β (PDGFRβ)* , 2005, Journal of Biological Chemistry.
[145] T. Ferkol,et al. IL-8 Released Constitutively by Primary Bronchial Epithelial Cells in Culture Forms an Inactive Complex with Secretory Component1 , 2001, The Journal of Immunology.
[146] M. Rusnati,et al. Heparin derivatives as angiogenesis inhibitors. , 2003, Current pharmaceutical design.
[147] F. Soncin,et al. Interaction of Heparin with Human Angiogenin* , 1997, The Journal of Biological Chemistry.
[148] M. Nugent,et al. Regulation of Vascular Endothelial Growth Factor Binding and Activity by Extracellular pH* , 2003, Journal of Biological Chemistry.
[149] D. Webb,et al. Transforming growth factor beta isoform 2-specific high affinity binding to native alpha 2-macroglobulin. Chimeras identify a sequence that determines affinity for native but not activated alpha 2-macroglobulin. , 1994, The Journal of biological chemistry.
[150] G. Neufeld,et al. Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis , 2004, Cancer Research.
[151] H. Ueno,et al. A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. , 1992, The Journal of biological chemistry.
[152] T L Blundell,et al. Crystal structures of NK1–heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor , 2001, The EMBO journal.
[153] D. Spillmann,et al. Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.
[154] P. Dell’Era,et al. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts , 2002, Oncogene.
[155] G. Taraboletti,et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.
[156] M. Rusnati,et al. Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. , 1994, The Biochemical journal.
[157] P. Bornstein,et al. Thrombospondin 2, a matricellular protein with diverse functions. , 2000, Matrix biology : journal of the International Society for Matrix Biology.
[158] G. Martiny-Baron,et al. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. , 1997, Cancer research.
[159] L. Szilák,et al. Interleukin-8 binds to syndecan-2 on human endothelial cells. , 2004, The Biochemical journal.
[160] G. Davis,et al. This Review Is Part of a Thematic Series on Vascular Cell Diversity, Which Includes the following Articles: Heart Valve Development: Endothelial Cell Signaling and Differentiation Molecular Determinants of Vascular Smooth Muscle Cell Diversity Endothelial/pericyte Interactions Endothelial Extracellu , 2022 .
[161] K. Preissner,et al. Molecular Interactions and Functional Interference between Vitronectin and Transforming Growth Factor-β , 2002, Laboratory Investigation.
[162] H. Vetter,et al. Gangliosides GM1, GM2 and GM3 inhibit the platelet-derived growth factor-induced signalling transduction pathway in vascular smooth muscle cells by different mechanisms. , 1996, European journal of cell biology.
[163] E. Chambaz,et al. Alpha 2-macroglobulin: a binding protein for transforming growth factor-beta and various cytokines. , 1996, Hormone research.
[164] M. Rusnati,et al. Functional Domains of Basic Fibroblast Growth Factor: Possible Role of Asp‐Gly‐Arg Sequences in the Mitogenic Activity of bFGF , 1991, Annals of the New York Academy of Sciences.
[165] P. Maher,et al. High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells--implications for the modulation of FGF-2 , 1995, The Journal of cell biology.
[166] T. Nakamura,et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. , 1998, Gastroenterology.
[167] S. Soker,et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.
[168] M. Rusnati,et al. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form , 1989, Journal of cellular physiology.
[169] Shay Soker,et al. Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.
[170] M. Giacca,et al. The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists* , 1998, The Journal of Biological Chemistry.
[171] M. Maio,et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies , 2003, Journal of cellular physiology.
[172] Álvaro R. Osornio-Vargas,et al. Differential Binding and Regulation of Platelet-derived Growth Factor A and B Chain Isoforms by α2-Macroglobulin (*) , 1995, The Journal of Biological Chemistry.
[173] M. Rusnati,et al. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans , 1996, International journal of clinical & laboratory research.
[174] Antonio Facchiano,et al. Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. , 2002, Blood.
[175] M. Tessier-Lavigne,et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function , 2003, Nature.
[176] M. Giacca,et al. Interaction of HIV-1 Tat Protein with Heparin , 1997, The Journal of Biological Chemistry.
[177] P. Hogg,et al. Interaction of platelet-derived growth factor with thrombospondin 1. , 1997, The Biochemical journal.
[178] D. Ribatti,et al. Integrin &agr;V&bgr;3 as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo , 2005 .
[179] M. Lyon,et al. The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific* , 1997, The Journal of Biological Chemistry.
[180] M. Giacca,et al. Identification of Specific Molecular Structures of Human Immunodeficiency Virus Type 1 Tat Relevant for Its Biological Effects on Vascular Endothelial Cells , 2000, Journal of Virology.
[181] A. Isacchi,et al. Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli. , 1992, European journal of biochemistry.
[182] R. Ross,et al. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[183] T. Shiomi,et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF‐induced angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[184] C. McArthur,et al. Amplification of extracellular matrix and oncogenes in tat-transfected human salivary gland cell lines with expression of laminin, fibronectin, collagens I, III, IV, c-myc and p53. , 2001, Archives of oral biology.
[185] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[186] D. Rifkin,et al. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor , 1990, The Journal of cell biology.
[187] R. Ross,et al. Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences , 1992, The Journal of cell biology.
[188] M. Mrksich,et al. Direct Cell Adhesion to the Angiopoietins Mediated by Integrins* , 2001, The Journal of Biological Chemistry.
[189] M. Noda,et al. α4β1- and α6β1-integrins are functional receptors for midkine, a heparin-binding growth factor , 2004, Journal of Cell Science.
[190] N. Galili,et al. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. , 2000, Cancer research.
[191] Y. Tabata,et al. Type I collagen can function as a reservoir of basic fibroblast growth factor. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[192] David C West,et al. Interactions of Multiple Heparin Binding Growth Factors with Neuropilin-1 and Potentiation of the Activity of Fibroblast Growth Factor-2* , 2005, Journal of Biological Chemistry.
[193] D. Schuppan,et al. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. , 2005, Biochemical and biophysical research communications.
[194] G. Plowman,et al. Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[195] A. Sahni,et al. FGF‐2 but not FGF‐1 binds fibrin and supports prolonged endothelial cell growth , 2003, Journal of thrombosis and haemostasis : JTH.
[196] D. Gospodarowicz,et al. Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.
[197] J. Courty,et al. Pleiotrophin inhibits HIV infection by binding the cell surface‐expressed nucleolin , 2005, The FEBS journal.
[198] M. Ziche,et al. Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. , 1999, Molecular biology of the cell.
[199] R. Alon,et al. TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein. , 1994, Journal of immunology.
[200] A. Aszódi,et al. Functional consequences of integrin gene mutations in mice. , 2001, Circulation research.
[201] E. Nilsson,et al. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. , 1991, The Journal of clinical investigation.
[202] James R. Knight,et al. A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae , 2000, Nature.
[203] D. Cheresh,et al. Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.
[204] K. J. Brown,et al. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. , 1994, Biochemistry.
[205] Marco Presta,et al. Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[206] Q. Yu,et al. Angiopoietin-3 Is Tethered on the Cell Surface via Heparan Sulfate Proteoglycans* , 2004, Journal of Biological Chemistry.
[207] M. Iruela-Arispe,et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. , 1999, Circulation.
[208] P. Dijke,et al. TGF-h receptor function in the endothelium , 2005 .
[209] F. López‐Casillas,et al. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. , 2001 .
[210] Dan M. Bolser,et al. Visualisation and graph-theoretic analysis of a large-scale protein structural interactome , 2003, BMC Bioinformatics.
[211] R. Iozzo,et al. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. , 2001, The Journal of clinical investigation.
[212] P. Dell’Era,et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.
[213] Shay Soker,et al. VEGF165 mediates formation of complexes containing VEGFR‐2 and neuropilin‐1 that enhance VEGF165‐receptor binding , 2002, Journal of cellular biochemistry.
[214] D. Ribatti,et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. , 2001, The Journal of biological chemistry.
[215] A. Bikfalvi,et al. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. , 1998, Blood.
[216] M. Giacca,et al. Thrombospondin‐1/HIV‐1 Tat protein interaction: modulation of the biological activity of extracellular Tat , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[217] H. Avraham,et al. VEGF165 requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells , 2001, Oncogene.
[218] E. Ruoslahti,et al. Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β3Integrin through Its Extracellular Domain* , 2000, The Journal of Biological Chemistry.
[219] A. Mori,et al. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. , 2000, International journal of oncology.
[220] Wen-Fang Tseng,et al. LRP‐1/TβR‐V mediates TGF‐β1‐induced growth inhibition in CHO cells , 2004 .
[221] M. O’Connor-McCourt,et al. Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. , 1987, The Journal of biological chemistry.
[222] E. Papadimitriou,et al. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. , 2004, The international journal of biochemistry & cell biology.
[223] S. Ladisch,et al. Shedding of gangliosides by human medulloblastoma cells. , 1997, Experimental cell research.
[224] D. Hicklin,et al. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. , 1994, The Journal of biological chemistry.
[225] G. Taraboletti,et al. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[226] Benito Casu,et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. , 2004, Glycobiology.
[227] G. Neufeld,et al. Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.
[228] I. Vlodavsky,et al. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. , 2001, The Journal of clinical investigation.
[229] Barbara Bottazzi,et al. PTX3 inhibits angiogenesis Selective recognition of fibroblast growth factor-2 by the long pentraxin , 2013 .
[230] John M. Whitelock,et al. The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.